A meta-analysis of four large randomised controlled trials that examined the neoadjuvant addition of lapatinib to trastuzumab plus chemotherapy in patients with early HER2-positive breast cancer: NeoALTTO, CALGB 40601, NSABP B41, and CHER-LOB, demonstrated that a dual HER2-blockade with trastuzumab and lapatinib was associated with significantly improved outcomes compared to treatment with trastuzumab alone, and could separately reduce the risk of relapse and death by 38% and 35% [7–11]. The gene discussed is ERBB2; the disease is breast carcinoma.